VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO 2022 | Recent advances in the management of STS

Patrick Schöffski • 9 Sep 2022
ESMO 2022
Sarcoma
Molecular Profiling

Patrick Schöffski, MD, MPH, KU Leuven, Leuven, Belgium, discusses treatment strategies for soft tissue sarcomas (STS), highlighting heterogeneity of the disease as well as recent advances in the identification of molecular drivers of STS. Prof. Schöffski touches on the development of MDM2-targeting agents as a potential therapeutic avenue for this patient population. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

More from Patrick Schöffski

0:51
BI 907828: targeting MDM2 in solid tumors
Patrick Schöffski • 9 Sep 2022
2:02
Phase I dose-escalation and expansion study evaluating BI 907828 in patients with solid tumours
Patrick Schöffski • 9 Sep 2022

Related Videos

1:36
Trabectedin and pazopanib: an indirect comparison of their ability to treat LMS
Robin Jones
1:04
How has the trabectedin extended access program benefited sarcoma patients?
Robin Jones
2:06
The current state of drug development against sarcomas
Robin Jones
5:17
Response rates to immunotherapy in sarcoma patients and implications for future therapies
Gary Schwartz • 3 Jun 2016
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals